PTSD Treatments: What the Evidence Actually Says

Three Percent of Americans, Every Year

Post-traumatic stress disorder affects approximately 3.5% of the US adult population annually — about 9 million people — and up to 20% of combat veterans returning from Iraq and Afghanistan. Globally, the WHO estimates a lifetime prevalence of 3.9% in the general population, rising to 10–30% among individuals exposed to high-magnitude traumas such as sexual assault, combat, or torture. Despite this scale and the existence of highly effective treatments developed since the 1980s, fewer than half of people with PTSD receive evidence-based care. The treatment gap is not a knowledge gap — it is a delivery gap.

DSM-5 Diagnostic Architecture

The DSM-5 (2013) reorganized PTSD into four symptom clusters, removing it from the anxiety disorders chapter into a new category of Trauma- and Stressor-Related Disorders. The restructuring recognized that PTSD often presents primarily as dysphoria, anger, or guilt rather than fear — features the anxiety disorder classification obscured.

Duration must exceed one month and produce significant functional impairment. The "with dissociative symptoms" specifier captures the approximately 15% of cases featuring prominent depersonalization or derealization.

First-Line Treatments: PE and CPT

Both the VA/DoD Clinical Practice Guidelines and the American Psychological Association designate prolonged exposure (PE) and cognitive processing therapy (CPT) as first-line treatments with the strongest evidence base. Both produce comparable outcomes; the choice between them depends on patient preference and clinical presentation.

Both treatments produce response rates of 60–80% in clinical trials, though real-world effectiveness studies show somewhat lower rates due to comorbidity, ongoing stressors, and motivation factors. They work. The challenge is access.

EMDR: Mechanism Debate Persists

Eye Movement Desensitization and Reprocessing (EMDR), developed by Francine Shapiro in 1987, is designated as an evidence-based treatment for PTSD by the WHO, APA, and VA/DoD. However, its proposed mechanism — that bilateral eye movements during trauma recall accelerate information processing — remains scientifically contested. Multiple dismantling studies have found that EMDR without the eye movement component produces equivalent outcomes, suggesting that the therapeutic value lies in structured trauma exposure and cognitive processing rather than the eye movements themselves.

This does not diminish EMDR's clinical utility: for patients who find direct trauma narration too distressing, EMDR's structure allows trauma processing at a managed distance. Mechanism questions are scientifically important; clinical effectiveness questions are separately answered. Both can be true simultaneously.

MDMA-Assisted Therapy: Phase 3 Results

The most significant recent development in PTSD treatment is MDMA-assisted therapy (MDMA-AT), investigated by MAPS (Multidisciplinary Association for Psychedelic Studies) in Phase 3 trials. MDMA is administered in two or three sessions, each 8 hours long, embedded within an extended psychotherapy protocol.

The MAPP1 Phase 3 trial (2021, n=90) found that 67% of participants in the MDMA-AT arm no longer met PTSD diagnostic criteria after treatment, compared to 32% in the placebo-plus-therapy arm. The MAPP2 trial (2023, n=104) showed 71.2% response for MDMA-AT versus 47.6% for placebo-plus-therapy. These are the largest effect sizes recorded for any PTSD intervention in Phase 3 trials. The FDA declined to approve MDMA-AT in 2024, citing concerns about blinding methodology and the replicability of results — a decision contested by researchers.

• MDMA's mechanism: acute release of serotonin, dopamine, and oxytocin reduces amygdala reactivity and defensiveness while enhancing trust and social engagement, creating a window for trauma processing.
• The treatment is therapist-assisted, not self-administered — the therapeutic relationship is integral to outcomes.
• Adverse effects in trials were generally mild and transient; no evidence of abuse or addiction in treatment contexts.

Somatic Approaches and Body-Centered Therapies

Somatic Experiencing (SE), developed by Peter Levine, and Sensorimotor Psychotherapy operate on the premise that trauma is stored in the body as unresolved physiological activation — incomplete defensive responses that remain frozen after the threat has passed. These approaches track body sensation, posture, and movement as primary clinical material rather than narrative or cognition.

The evidence base for SE is less extensive than for PE or CPT — a 2022 systematic review found only four RCTs — but effect sizes are moderate and dropout rates are low, suggesting acceptability advantages for patients who find verbally-focused trauma processing retraumatizing. Somatic approaches are particularly prominent in complex trauma treatment.

Stellate Ganglion Block: Emerging Evidence

The stellate ganglion block (SGB) — an anesthetic injection into a sympathetic nerve cluster in the neck — has emerged as a potential biological intervention for PTSD. Proposed mechanism: the injection may reset sympathetic nervous system hyperactivation by reducing nerve growth factor expression. A 2020 randomized trial (Lipov/Hickey) in active military personnel found significant PTSD symptom reduction at 8 weeks post-injection versus sham procedure. Larger trials are ongoing. SGB is not yet an established standard treatment, but the rapidity of effect — within 30 minutes — is clinically remarkable.

Complex PTSD: The ICD-11 Distinction

The ICD-11 (2018) introduced Complex PTSD (CPTSD) as a distinct diagnosis alongside PTSD. CPTSD includes the standard PTSD criteria plus three additional clusters reflecting disturbances in self-organization: affect dysregulation, negative self-concept (persistent shame, guilt, worthlessness), and disturbances in relationships (difficulty sustaining close relationships, feeling detached from others).

CPTSD typically results from prolonged or repeated trauma — childhood abuse, domestic violence, captivity — rather than single-incident exposure. Treatment generally requires more sessions, greater emphasis on stabilization before trauma processing, and skills-based components (DBT, STAIR) targeting affect regulation before trauma-focused work begins. Jumping directly to exposure in undertreated CPTSD can destabilize rather than heal.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified mental health professional for diagnosis and treatment.